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Extracellular matrixMesenchymal stem cells (MSCs) have recently made signiﬁcant progress with multiple clinical trials
targeting modulation of immune responses, regeneration of bone, cartilage, myocardia, and diseases like
Metachromatic leukodystrophy and Hurler syndrome. On the other hand, the use of human embryonic and
induced pluripotent stem cells (hPSCs) in clinical trials is rather limited mainly due to safety issues. Only
two clinical trials, retinal pigment epithelial transplantation and treatment of spinal cord injury were
reported. Cell doses per treatment can range between 50,000 and 6 billion cells. The current 2-dimensional
tissue culture platform can be used when low cell doses are needed and it becomes impractical when
doses above 50 million are needed. This demand for future cell therapy has reinvigorated interests in the
use of the microcarrier platform for generating stem cells in a scalable 3-dimensional manner.
Microcarriers developed for culturing adherent cell lines in suspension have been used mainly in vaccine pro-
duction and research purposes. Since MSCs grow as monolayers similar to conventional adherent cell lines,
adapting MSCs to a microcarrier based expansion platform has been progressing rapidly. On the other
hand, establishing a robust microcarrier platform for hPSCs is more challenging as these cells grow in multi-
layer colonies on extracellular matrices and are more susceptible to shear stress.
This review describes properties of commercially available microcarriers developed for cultivation of anchor-
age dependent cells and present current achievements for expansion and differentiation of stem cells. Key is-
sues such as microcarrier properties and coatings, cell seeding conditions, medium development and
improved bioprocess parameters needed for optimal stem cell systems are discussed.
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In this review, we cover the two broad classes of anchorage
dependent stem cells (human mesenchymal and pluripotent stem
cells) with the greatest promises for cell therapy success in clinical
trials. Both of these cell types are universally grown in 2 dimensional
(2D) cultures. However for large scale production, there is a shift
towards 3 dimensional (3D) suspension cultures, in particular with
the use of microcarriers (MCs) in bioreactors. This article begins
with reviews on these two cell types, their growth requirements,
use in clinical trials and potential applications. MC technology and
their usage in stem cell expansion and differentiation are subsequent-
ly depicted. Challenges still to be overcome are also highlighted, as
the production of large doses of cells becomes necessary for late
stage clinical trials and commercialization.
2. Multipotent and pluripotent stem cells: source, mode of growth
and applications in clinical trials
2.1. Sources of multipotent/mesenchymal stem cells
Multipotent or mesenchymal stem cells (MSCs) are attracting
increasing interest for possible application in cell therapies. MSCs
encompass a broad range of anchorage dependent ﬁbroblast-like
cells which can be obtained from bone marrow aspirates, skeletal
muscle connective tissue, human trabecular bones, adipose tissue,
periosteum, fetal blood and liver, and umbilical cord blood, as re-
viewed by Oh and Choo (2011). Homogeneous MSCs can also be
derived from human embryonic stem cells (hESCs) (Lian et al., 2007;
Olivier et al., 2006). MSC express the CD29, CD44, CD73, CD90,
CD105 and primitive Stro-1 markers (Dominici et al., 2006). They
can proliferate in vitro and differentiate into mesoderm-type lineages,
including osteoblasts, chondrocytes, adipocytes, myocytes and vascu-
lar cells. Due to this ability, MSC provide a versatile source of progen-
itor cells for research and clinical applications in the ﬁeld of tissue
regeneration.
2.2. Mode of growth
MSCs are typically grown on plastic tissue culture dishes as mono-
layers with no additional coatings (Fig. 1A and C). Basal media
supplemented with fetal calf serum between 5 and 10% is widely
utilized, but its use in the context of clinical applications is associatedwith several risks such as viral and prion transmission (Bernardo et al.,
2007; Govindasamy et al., 2011; Shahdadfar et al., 2005) or immu-
nological reactions (Selvaggi et al., 1997; Tuschong et al., 2002). Sever-
al new serum free media such as MesenCult®-XF Medium (Stemcell
Technologies), StemPro®MSC SFM (Life Technologies), MSC Nutristem®
XF Medium (Biological Industries), BD Mosaic™ (Becton Dickinson)
in conjunction with surface coatings with proprietary extracellu-
lar matrices are now becoming available from companies such as
Life Technologies, StemCell Technologies, Biological Industries and
Becton Dickinson.2.3. Differentiation capabilities
The tri-lineage differentiation capability of MSCs into osteoblasts,
adipocytes, and chondrocytes has been evaluated by many groups. Os-
teogenesis requires MSCs to be incubated with β-glycerol-phosphate,
ascorbic acid-2-phosphate, dexamethasone and fetal bovine serum.
MSCs should reveal osteoblastic morphology together with high ex-
pression of alkaline phosphatase and calcium deposition. To view oste-
oblast generation, Von Kossa staining is a technique which subjects cell
cultures to silver nitrate solution. Calcium is then reduced by light and
silver deposits generated, which can be visualized by microscopy
(Chase et al., 2010). For adipogenesis, MSC cultures are incubated
with isobutylmethylxanthine to form adipocytes with lipid vacuoles.
This process is induced by nuclear receptor, PPAR-γ, transcription
factors and fatty acid synthetase. Lipid vacuoles are detected by oil red
O staining; a fat soluble-oil for staining lipid and fat in culture sections
(Chase et al., 2010). Chondrogenesis is performed in a 3D culture pellet,
with a serum-free nutrientmedium and transforming growth factor-β3
(TGF-β3). Under such conditions,MSCs quickly change theirﬁbroblastic
appearance and express cartilage-speciﬁc matrix-layers ﬁlled with
glycosaminoglycans. Toluidine blue indicator, a polychromatic dye, is
used to stain for glycosaminoglycan-containing components (Chase et
al., 2010; Zhang et al., 2011). In addition, such differentiated MSCs can
generate type II collagen, another cartilage component (Zhang et al.,
2011).
Other than these three lineages, MSCs are believed to be able
to differentiate into myoblasts, cardiomyocytes and even neurons.
Formation of cells of non-mesodermal origin may be a result of a
phenomenon known as “stem cell plasticity”, a transdifferentiation
process in which organ-speciﬁc stem cells are no longer restricted
to forming the differentiated cell types of the tissue where they reside
(Lakshmipathy and Verfaillie, 2005).
Fig. 1. Bioprocessing of hMSCs. Illustrations showing phase contrast image of MSC on (A) 2D monolayer and (B) 3D MCs (Cytodex 3). Scale bars indicate 200 μm. Expansion of MSC
can be carried out from (C) 2D tissue culture ﬂasks to (D) multilayer ﬂask (Corning HYPERFlask®) or (E) MCs using disposable Corning 250 ml spinner ﬂask, (F) 5 l bioreactor and
then to 70 l stainless-steel bioreactor.
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A recent review of clinical trials for stem cell therapies describes
the use of MSC in addressing diseases ranging from cancer, diabetes,
bone, cartilage, heart, gastrointestinal, immune and neurodegenerative
diseases (Trounson et al., 2011). Below, we highlight a few late stage
trials where signiﬁcant cell doses are needed for these therapies.
2.4.1. Immuno-modulatory therapy
2.4.1.1. Acute graft-versus-host disease. MSCs have shown promising
clinical potential for immuno-modulatory therapy. Osiris Therapeutics'
product, Prochymal, which are MSCs expanded from healthy adults'
bone marrow has been evaluated in phase III clinical trials for both
steroid refractory and acute graft-versus-host disease (GVHD). In a
successful phase II clinical trial, human MSCs were used to treat de
novo acute GVHD. Patients suffering from grades II–IV GVHD were
randomized for two Prochymal dosages of 2 or 8 million MSCs per kg,
together with infusion of corticosteroids. Prochymal achieved 94% in
overall response rate with an outstanding complete remission rate of
77% from the 32 patients. Most of these GVHD symptoms disappeared
by day 18 afterMSC injection. In addition there was neither administra-
tive harm nor ectopic tissue development. Regardless of the dosage
levels, safety and efﬁcacy levels remained the same, showing the
remarkable ability of MSCs for the treatment of acute GVHD (Kebriaei
et al., 2009). Prochymal has now received approval for clinical use in
pediatric patients in Canada. Since then there have been other studies
published of MSCs for the treatment of acute GVHD (Herrmann et al.,
2012; Kuzmina et al., 2012).
2.4.1.2. Crohn's disease. Prochymal is also applied in clinical trials for
the treatment of moderate to severe Crohn's disease. In a phase I
trial, autologous derived MSCs reduced the Crohn's disease activityindex in 9 patients with 2 doses of cell infusion (Duijvestein et al.,
2010). In phase II studies, patients' inﬂamed intestines showed
diminishing inﬂammatory conditions and crypt regeneration follow-
ing Prochymal treatment. In an open label trial, 10 patients with
Crohn's disease were randomly selected, who had failed to show im-
provement by treatment with steroids, Methotrexate, and Remicade
previously. By day 9 of Prochymal injection, there were signs of
recovery such as intestinal inﬂammation and ulceration reduction as
well as crypt formation in some patients. By day 28, every patient
saw a drastic drop in Crohn's disease severity and at the same time,
tolerated Prochymal relatively well, suggesting that MSCs may be
suitable to treat Crohn's disease. Unfortunately, the phase III trial of
Prochymal for Crohn's disease halted patients' enrolment because of
a design ﬂaw which resulted in signiﬁcantly higher than expected
placebo response rates (Allison, 2009). Osiris has since had an ex-
tended evaluation of the trial and has successfully completed the
study but has not yet published.
2.4.2. Bone regeneration
Osteogenesis Imperfecta (OI), a bone disease can be treated with
MSC transplantation. Due to the production of abnormal type I colla-
gen in bones, slow bone development, frequent fractures, and bone
distortion occurs. Horwitz et al. (1999) transplanted bone marrow
cells from HLA-identical siblings to OI patients and showed about
2% of the osteoblasts in recipient's bone marrow came from the
donor. These MSC can develop into normal osteoblasts, leading to
fast bone development and reduced fracture frequencies (Horwitz
et al., 1999).
Subsequent trials done with children resulted in signiﬁcant gain
in total body length with a median of 7.5 cm, six months post trans-
plantation. Bone mineral content improved by 45–77% of baseline
values and frequency of fractures dropped from 10 to 2. Follow-up
investigations showed that the introduction of puriﬁed allogenic
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treatment of OI (Horwitz et al., 2002).
A more recent clinical trial makes use of in utero MSC transplanta-
tion in patients with severe OI. Findings showed that allogenic
fetal MSC can engraft and differentiate into bone in the human fetus
even when the recipient is immuno-competent and HLA-incompatible
(Le Blanc et al., 2005). The Children's Hospital of Philadelphia in
the USA is currently recruiting study subjects for their phase I
study to assess the safety and feasibility of repeated infusions of
MSC in children with OI (ClinicalTrials.gov Identiﬁer: NCT01061099).
MSC therefore appears particularly promising for bone regeneration.2.4.3. Cartilage regeneration
The application of autologous bone marrow derived MSCs into
patients with Osteoarthritis has been reported. Twelve patients re-
ceived MSC injections into articular cartilage defects located in their
knee joints and results were compared with a control group without
MSC treatment. MSC transplantation resulted in defects being cov-
ered with white soft tissue that displayedmore desirable arthroscopic
and histological grading properties than the controls (Wakitani et al.,
2002). This study demonstrated the possibility of using MSCs for car-
tilage repair. A clinical study of articular cartilage regeneration is
being investigated using umbilical cord blood-derived MSCs to treat
older patients who possess large defects which do not heal easily.
This study was conducted by MediPost which has recently completed
a phase III clinical trial comparing the efﬁciency and safety between
their product, CARTISTEM® (allogeneic-unrelated umbilical cord
blood derived MSCs), and microfracture treatment (controls) in pa-
tients with knee articular cartilage defects. This product was recently
approved by Korean Food and Drug Administration for clinical use.Table 1

















40 to 100 ClinicalTrials.gov Identiﬁer:
NCT014290122.4.4. Myocardium regeneration
In a recent human study, patients were chosen at random for the
intracoronary introduction of autologous bone marrow MSC follow-
ing myocardial infarction (MI). After three months, it was observed
that the heart's damaged region has reduced by a greater amount,
coupled with more signiﬁcant improvements in contractility and
heart function versus patients who underwent standard therapy. Al-
though the exact mechanism behind myocardium regeneration re-
mains unknown, the study shows the promise of MSCs for tissue
engineering and regeneration applications (Strauer et al., 2002).
Presently, Osiris Therapeutics is starting phase II clinical trials for the
treatment of acute MI using Prochymal. Concurrently, they are also
conducting a phase I randomized; double-blind, placebo-controlled,
dose escalation, andmulti-center study to determine the safety of infus-
ing ex-vivo cultured adult MSCs (Provacel) following acute MI (Allison,
2009).Myocardial
infarction
20 to 200 Strauer et al. (2002) and





100 to 900 Herrmann et al. (2012) and
Kuzmina et al. (2012)
Skeletal disorders 140 to 700 Koç et al. (2002)
Crohn's disease 120 to 1200 Duijvestein et al. (2010) and





3000 to 6000 Horwitz et al. (1999) and
Le Blanc et al. (2005)
hESC Macular
degeneration
0.05 to 0.2 Schwartz et al. (2012)
ClinicalTrials.gov Identiﬁer:
NCT01344993
Spinal cord injury 2 Bretzner et al. (2011)
ClinicalTrials.gov Identiﬁer:
NCT01217008
Note: Rowley et al. (2012) estimated lot sizes of more than 100 billion cells are not
readily achievable using 2D cultivation method.2.4.5. Metachromatic leukodystrophy (MLD) & Hurler syndrome
Metachromatic leukodystrophy (MLD) or Hurler's syndrome is a
disease that results in severe skeletal and neurological disorders. A
clinical trial of patients with MLD, who previously underwent suc-
cessful bone marrow transplantation from an HLA-identical sibling,
has been reported. MSC from a bone marrow aspirate of the original
donor was infused into these patients. Of the six patients with MLD,
four showed signiﬁcant improvements in nerve conduction velocities
after MSC transplantation (Koç et al., 2002). Furthermore, the bone
mineral density either improved or remained unchanged in all pa-
tients. More importantly, there were no apparent adverse effects in
all patients after MSC infusion. Thus allogenic MSC infusion may be
a suitable treatment of patients with MLD.
Based on the review of a selected range of disease types and inju-
ries, it appears that tens of millions to billions of MSC will be required
per patient per transplantation (Table 1).3. Pluripotent stem cells, hESCs and hiPSCs
The ﬁrst human embryonic stem cells (hESCs) were derived by
James Thomson and his co-workers in 1998, using frozen or fresh
blastocysts left over from infertility treatment of couples that had
undergone in vitro fertilization (IVF). The blastocysts were cultured
from the initial cleavage stage embryos and 14 inner cell masses
(ICM) were isolated from the blastocysts. From these, ﬁve cell lines
were derived (Thomson et al., 1998). Besides Thomson's method,
hESC can also be derived from non-viable embryos that are produced
by IVF that have undergone irreversible cessation of cell division and
are no longer suitable for the purpose of reproduction. However,
these embryos still retain some normal blastomeres suitable for the
derivation of stem cells.
In 2007, Takahashi and Yamanaka discovered a new method of
generating human induced pluripotent stem cells (hiPSCs) which
have pluripotency properties similar to hESCs, by transfecting 4
genes to human ﬁbroblasts (Takahashi et al., 2007). This opened the
ﬂoodgates of new approaches for creating hiPSCs using Retroviruses,
Lentiviruses, Sendai virus, mini-circle plasmids, mRNA, microRNA and
recombinant proteins (Robinton and Daley, 2012). hiPSC express
pluripotency markers such as Oct4, Nanog, Sox2, and surface antigens
SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81. Many cell types have now
been reprogrammed to hiPSC such as ﬁbroblasts, MSC, fat and blood
cells thereby enabling the modeling of a range of hematological, neu-
rological, metabolic, cardiovascular, and immunodeﬁciency diseases
(Robinton and Daley, 2012).
3.1. Mode of growth
Initially, hESCs were derived on mouse feeder layers (Thomson
et al., 1998). Subsequently, a variety of stromal layers derived from
human feeders and different cell sources were found to be able to
support long term hESC culture (Choo et al., 2006). In the next
phase, researchers began to look for fully deﬁned media devoid of
the use of feeders. A deﬁned media where every component and
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peutic context. It is particularly desirable to eliminate animal derived
products due to the potential for transmission of pathogens to the
cells. The International Stem Cell Initiative (TISCI) Consortium con-
ducted a comprehensive comparison of 9 different deﬁned culture
systems for feeder free propagation of hESCs in 4 separate laboratories
and found that most of the formulations did not support maintenance
of hESCs for even a relatively short period of the study (Consortium
et al., 2010). The two commercial media (mTeSR®1 hESC SFM and
StemPRO® hESC SFM), are the most robust in terms of long term
support of hESCs. This may be attributed to the subtleties in media
preparation.
The non-deﬁned extracellular matrix (ECM) extract, Matrigel, has
been used traditionally as a surface matrix for hESC culture. A study
combined four extracellular matrix proteins: collagen IV, ﬁbronectin,
laminin and vitronectin, to replace Matrigel for the long-term expan-
sion of hESCs in deﬁned mTeSR®1 hESC SFM (Ludwig et al., 2006).
Others have tried deﬁned ECMs such as human ﬁbronectin (Amit
and Itskovitz-Eldor, 2006), human recombinant laminins 111, 332
(Miyazaki et al., 2008), and 511 (Rodin et al., 2010) and vitronectin
(Braam et al., 2008; Yap et al., 2010). Recently, Melkoumian et al.
(2010) described a synthetic surface, consisting of peptide sequences
conjugated to an acrylate polymer, which sustains the propagation of
hESCs over 20 passages in deﬁned medium. hESCs were also able to
form cardiomyocytes on the peptide surfaces. Using an approach
that does not require a hydrogel, Kolhar et al. (2010) report that
cyclic-RGD peptide sequences conjugated to tissue culture polysty-
rene were suitable for propagating hESCs in a deﬁned medium. Both
studies veriﬁed hESC quality by performing karyotype analysis and
pluripotency assays.
3.2. Differentiation capabilities
The versatility of both hESCs and hiPSCs to become multiple cell
types in the body makes them interesting candidates for studies of
developmental biology. It is expected that these cells may eventually
ﬁnd applications in cell therapy. Typically, in vitro differentiation of
hESCs into the three germ layers requires the initial formation of em-
bryoid bodies (EBs), which are cell aggregates in suspension. EBs are
able to differentiate into several cell lineages such as primitive endo-
derm, deﬁnitive endoderm, mesoderm, ectoderm, and trophectoderm
(Doetschman et al., 1985; Itskovitz-Eldor et al., 2000; Takahashi et al.,
2007; Yu et al., 2007). Until now, neurons, glia, endothelial cells,
cardiomyocytes, keratinocytes, hepatocyte-like cells, hematopoietic
precursors, osteogenic cells, insulin-producing cells, prostate tissue,
adipocytes and melanocytes have been differentiated from hESC
(Gepstein, 2002; Keller, 2005; Odorico et al., 2001; Pera and Trounson,
2004).
An example of an ectoderm lineage is neural differentiation. In the
presence of ﬁbroblast growth factor 2 (FGF-2), neural tube-like struc-
tures can be formed from EBs. The neural precursors were then isolat-
ed from these EBs. With FGF-2 withdrawal, these precursors can be
further differentiated into neurons, astrocytes and oligodendrocytes.
Transplantation of precursors into the brain of a neonatal mouse,
showed that they were incorporated into different parts of the
brain, where they formed both astrocytes and neurons (Zhang et al.,
2001).
An example of a mesoderm lineage is cardiomyocyte differentia-
tion. EBs plated on culture dishes coated with gelatin continued to
differentiate for 22 days after plating, with 8% of the EBs containing
areas which were contracting rhythmically. Cardiac speciﬁc transcrip-
tion factors and genes were expressed by the cells isolated from these
areas. In addition, the cells displayed a functional phenotype of fetal
human cardiomyocytes (Kehat and Gepstein, 2001).
hESCs have been differentiated to 80% deﬁnitive endoderm cells in
low serum and Activin A. More mature cells of the endodermal organsare produced from these deﬁnitive endoderm cells after transplanta-
tion under the kidney capsule (D'Amour et al., 2005). The endodermal
cell aggregates expressed various marker genes, such as HNF6, FOXA2
and PDX1 which indicated that they were of the pancreatic endoderm
(Kroon et al., 2008).
3.3. Potential applications and clinical trials
At present, there are only a handful of on-going therapies in
humans involving hESC (Table 1) compared to MSC where there are
123 (Trounson et al., 2011). The limited number of hESC related cell
therapy trials is partly due to concerns about the tumorigenicity of
these cells.
3.3.1. Spinal cord injury
The ﬁrst human trial of hESC for the treatment of spinal cord inju-
ry was approved by the Food and Drug Administration (FDA). Eight to
ten patients with severe spinal cord injuries were recruited in a phase
1 trial by Geron, to test the safety of the oligodendrocyte progenitor
cells (OPC). In this treatment, a cocktail of growth factors is used to
induce hESCs into OPCs before they are injected into the injured spi-
nal cord. Oligodendrocytes play a part in supporting neural cells to
restore nerve conduction. Earlier preclinical trials done in adult
rats showed that the transplanted hESC-derived OPC enhanced
remyelination and promoted the improvement of motor function.
The aim of the phase 1 clinical trial was to enhance the repair of the
myelin insulation around the nerve cells and thereby re-establish
the spinal cord's ability to transmit signals (Keirstead et al., 2005).
Unfortunately in early 2012, Geron made a business decision to stop
pursuing this clinical trial.
3.3.2. Retinal pigment epithelial (RPE) transplantation
RPE cells are a derivative of the neuroectoderm which are crucial
for the survival of photoreceptors. In age-related macular degenera-
tion (AMD), RPE cells degenerate and cannot be replaced. Studies
using animal models have shown that degenerated RPE cells can be
replaced by transplanting donor RPE cells, rescuing the host photore-
ceptors and thereby restoring visual function. hESC has recently been
shown to be an excellent source for generating RPE cells (da Cruz et
al., 2007). These hESC-derived RPE cells have shown similar gene
expression proﬁles resembling primary human RPE. Three previous
studies have made use of different protocols on mouse embryonic
stem cells (mESC) and hESC to form RPE cells prior to transplantation
and have found no evidence of any tumor formation, thus showing
the clinical promise of hESC-derived RPE cells in treating AMD (da
Cruz et al., 2007).
Recently, the FDA has approved the testing of hESCs for the treat-
ment of Stargardt's Macular Dystrophy (SMD) by Advanced Cell Tech-
nology Inc. (ACT). This rare disease destroys the retinal cells of
approximately 30,000 people worldwide. Currently, ACT has com-
pleted animal studies and is conducting a phase I trial to establish
the safety and tolerability of the RPE cells after transplantation into
the sub-retina of SMD patients in the US and UK. Preclinical trials in
rat models showed a visual performance improvement of 100% with-
out any undesirable effects in the treated rats when compared with
their untreated cohorts (Lu et al., 2009).
3.3.3. Models of disease and drug screening
As hiPSC can be generated from patient samples of a variety of dis-
eases, they can potentially be used in many disease models (Colman
and Dreesen, 2009). For example, hiPSCs could be useful models for
studying the development of patients with sporadic or familial
diseases, including Parkinson's disease, Alzheimer's disease, juvenile-
onset, type I diabetes mellitus, and Duchenne type muscular dystrophy
(Jang et al., 2012). They could also be used for drug screening for
cardiotoxicity to reduce the attrition rate of drugs in development
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generate hepatocytes of adult phenotype for studies of drug metabo-
lism. However, as a cell source for therapy it is still too early to tell,
due to their genetic and epigenetic abnormalities after reprogramming.
4. Microcarrier (MC) technology
The above section shows that large amount of cells are needed for
clinical therapies. Since clinical application of these cells will require
106 to 109 cells per treatment (Table 1), production of thousands of
treatment doses in conventional 2D culture can be challenging. We
estimate that cell doses of up to 50 million cells can be produced in
one 40 stack Nunc tray handled by robotic or manual manipulation.
However, when the demand increases this becomes extremely labor
intensive, costly, and impractical (Davie et al., 2012; Rowley et al.,
2012). One of the options for overcoming this obstacle would be a
MC based culturing technology. In the following sections, we will
describe the availability of MCs for anchorage dependent cells, their
properties and advantages compared to 2D culture. Thereafter, we
will describe the recent studies showing adaptation of commercial
MCs to expand and differentiate MSCs and hPSCs.
4.1. Culturing of anchorage dependent cells on MC
Traditionally anchorage dependent stem cells are propagated in
2D tissue culture surfaces. The restricted surface to volume ratio
offered by this classical technique creates a bottle neck in the produc-
tion of cells. In an attempt to provide systems that offer large accessi-
ble surfaces for cell growth in a small volume, a number of techniques
have been proposed: stacked plates (Wolfe et al., 2008), hollow ﬁbers
and packed bed reactors (Brandenberger et al., 2011). Since these
systems are non-homogeneous in their nature, they suffer from sev-
eral shortcomings: limited potential for scale up, difﬁculties in taking
cell samples, limited potential for measuring and controlling the
system and difﬁculties in maintaining homogeneous environmental
conditions throughout the culture. In order to overcome these limita-
tions, van Wezel (1967) developed the concept of the MC culturing
system. In this system, cells are propagated on the surface of small
solid particles suspended in the growth medium by slow agitation.
The cells would attach and grow to conﬂuence on the surface of the
MCs.
4.2. Advantages of the MC culturing systems
The MC system is a unit operation in which both monolayer and
suspension cultures are brought together. The MC surface is available
for cell growth while the mobility of MCs in the medium generates a
homogeneity that is similar to the suspension environment used in
traditional mammalian and microbial submerged cultures. The
major advantages of the MC system are listed below.
1. High surface to volume ratio which can be increased easily by
changing the MC concentration. A culture of 3 mg/ml Cytodex 1
MC culture can supply a surface area of 1.32 × 104 cm2 in 1 l
which is equivalent to 176 tissue culture ﬂasks with 75 cm2 each.
This single unit operation leads to reduction in laboratory space,
and the number of handling steps per cell, thus reducing labor
costs and risks of contamination.
2. A homogeneously stirred MC suspension culture allows monitoring
and controlling of various environmental parameters (e.g. pH, pO2,
concentration of medium components), leading to more reproduc-
ible cell culture. A representative cell sample can be taken for micro-
scopic observation and cell characterization.
3. MC cultures can be scaled up with ease in conventional stainless
steel or disposable bioreactors that are used for propagation of
suspended mammalian cells.4. Macroporous MCs can protect cells from shear stress created by the
stirrer, sparger or spin ﬁlter in the bioreactor (Blüml, 2007; Ng et al.,
1996).
5. MCs can enable scale up by cell to cell transfer without the use of
proteolytic enzymes (Blüml, 2007; Wang and Ouyang, 1999).
6. Perfusion cultures are easier to operate with MC culture since me-
dium can be easily harvested on line by ﬁltration or decantation
(Blüml, 2007; Butler et al., 1983; Serra et al., 2010).
7. MCs can be used for propagation of cells in 3D culture and for study-
ing co-cultures and cell–cell interactions (Martin et al., 2011).
8. Biodegradable MCs can be used as the scaffold for in vivo transplan-
tation of cells (Chung et al., 2008; Martin et al., 2011; Thomson et al.,
2010).
These unique properties illustrate the reasons for the extensive use
of MC cultures in viral vaccine production (Tree et al., 2001) and other
laboratory scale applications.
4.3. General requirements and properties of MCs
MCs were initially developed for supporting the growth of anchor-
age dependent mammalian cells (primary cells, diploid cell strains
and transformed cell lines). Various types of MCs were developed
(Table 2). Different MC properties can affect cell attachment, spread-
ing, growth and differentiation. The general requirements and physi-
cal properties are discussed below.
Functional attachment and growth supporting elements on the
MC surfaces are critical. The surface of a MC can be derivatized with
functional groups such as positively charged tertiary quaternary or
primary amines, gelatin, collagen, other extracellular matrix (ECM)
proteins and peptides (e.g. RGD peptide). The positively charged
MCs attract the cells (which are negatively charged), by electrostatic
forces. The optimal amount of positive charge was found to be
between 1 and 2 milliequivalents/g dry materials (for cross-linked
dextran or polyacrylamide beads derivatized with tertiary amines)
(Himes and Hu, 1987; Reuveny et al., 1981, 1983). At this level, cells
attach to the MCs efﬁciently (about 90% within 1 h) without negative
effect on cell growth. Coating with collagen or ECM protein results in
lower cell attachment but usually supports better growth of cells at
low inocula levels.
MCs can be produced in various shapes and sizes, spherical being
the most common. Each MC should have the dimensions that can fa-
cilitate cell growth for several doublings. In this way at the end of the
cell growth, each MC will support several hundred cells on its surface.
For spherical MCs, diameters of 100–230 μm are reported to be the
preferred size (Markvicheva and Grandﬁls, 2004). The size distribu-
tion of the spherical MC should be low (±25 μm) in order to prevent
uneven distribution of cells on the MCs. Density of the MC should be
slightly above 1 (1.02–1.05 g/ml) in order to maintain the MCs in
suspension at minimal agitation speed. Furthermore, the agitation
type and speed and oxygen delivery method need to be optimized
to prevent cell detachment and to minimize shear forces on the
cells. The matrix of the MC should be rigid enough in order to support
cell spreading and withstand any mechanical forces encountered
during the cell cultivation. Lastly, the MCs are preferred to be trans-
parent for direct observation of cells and heat tolerant for steam
sterilization.
4.4. Commercial MCs
A wide variety of MCs are available commercially (Table 2), giving
researchers an opportunity to choose the right one that meets the
demand of their speciﬁc targets. By examining the commercially
available MCs, it is possible to categorize the MCs into six groups:
Group 1 Non-porous smooth (e.g. polystyrene MCs) or microporous
MCs (e.g. Cytodex 1) with positive charges. These MCs are
Table 2
Commercial microcarriers and their features.
Type Microcarrier Matrix Dimension (pore size) Manufacturer Surface feature Density




DE-52 Cellulose Whatman/GEHealthcare Diethylaminoethyl (0.88–1.08
meq/g dry material)
0.9 g/ml
DE-53 Cellulose Cylindrical L 130 ± 60 μm
× Ø 35 ± 7 μm
Diethylaminoethyl
(1.8–2.2 meq/g dry material)
1.1 g/ml
QA-52 Cellulose Quaternary ammonium
(1.09 meq/g dry material)
1.2 g/ml
HLX II-170 Polystyrene Spherical Ø 170 ± 10 μm Thermo Scientiﬁc Triethylamine 1.12 g/ml
P Plus 102-L Polystyrene Spherical Ø 169 ± 44 μm Cationic charged 1.02 g/ml
FACT 102-L Polystyrene Spherical Ø 169 ± 44 μm Cationic charged and
Type I porcine collagen
1.02 g/ml
Collagen coated CGEN 102-L Polystyrene Spherical Ø 169 ± 44 μm Thermo Scientiﬁc Type I porcine collagen 1.02 g/ml
Cytodex 3 Dextran Spherical Ø 175 ± 36 μm GE Healthcare Denatured pig skin Type I collagen 1.04 g/ml
ECM coated Pro-F 102-L Polystyrene Spherical Ø 169 ± 44 μm Thermo Scientiﬁc Recombinant ﬁbronetin 1.02 g/ml
Non/Negative
charged
P 102-L Polystyrene Spherical Ø 169 ± 44 μm Thermo Scientiﬁc Uncoated 1.02 g/ml
2D MicroHex Polystyrene Hexagon L 125 μm × W 25 μm Tissue culture treated 1.05 g/ml
G2767 Glass Spherical Ø 180 ± 30 μm Sigma Aldrich Uncoated 1.03 g/ml
G2517 Glass Spherical Ø 120 ± 30 μm Uncoated 1.03 g/ml
G2892 Glass Spherical Ø 120 ± 30 μm Uncoated 1.04 g/ml
Macroporous Cultispher G Gelatin Spherical Ø 255 ± 125 μm
(10–20 μm)
Thermo Scientiﬁc Gelatin 1.03 g/ml
Cultispher S Spherical Ø 255 ± 125 μm
(10–20 μm)
Gelatin 1.03 g/ml
Cultispher GL Spherical Ø 255 ± 125 μm
(50–70 μm)
Gelatin 1.03 g/ml
Cytopore 1 Cellulose Spherical Ø 240 ± 40 μm
(30 μm)
GE Healthcare Diethylaminoethyl (0.9–1.2 meq/g
dry material)
1.03 g/ml
Cytopore 2 Diethylaminoethyl (1.65–1.95 meq/g
dry material)
1.03 g/ml
Weighted Cytoline 1 Polyethylene and silica Lens-shape L 2.1 ± 0.4 mm
× W 0.75 ± 0.35 mm (10–400 μm)
GE Healthcare A slight negative charge 1.32 g/ml
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monolayer of cells on the surface of the MC in stirred cul-
tures. This group includes also Whatman's anion exchange
celluloses (DE-53), cylindrical shaped MCs that have been
used successfully in culturing cell lines (BHK and MDCK)
(Reuveny et al., 1981, 1982).
Group 2 Collagen coated MCs (e.g. Cytodex 3 and FACT 102-L). These
MCs are chemically coupled with collagen and are suitable
for culturing sensitive cells with low plating efﬁciency. The
collagen coating is also designed to facilitate cell harvesting.
Group 3 ECM coated MCs (Pro-F 102-L). Pro-F 102-L is coated with
recombinant ﬁbronectin which is designed for culturing of
sensitive cells in serum free conditions.
Group 4 Non-charged MCs (e.g. Glass beads and tissue culture Poly-
styrene MC P 102-L). These MCs have similar surface prop-
erties as classical 2D tissue culture surfaces.
Group 5 MacroporousMCs (e.g. Cytopore and Cultispher).Macroporous
MCs with pore sizes in the range of 10–70 μm on the surface.
They provide higher cell surface areas for growth and offer bet-
ter mechanical protection to the cells from shear stress gener-
ated by stirrers, spargers or spin ﬁlters.
Group 6 Weighted MCs (Cytoline). These MCs are designed for use in
ﬂuidized bed perfusion cultures.
These commercial MCs have been designed according to the needs
for propagating anchorage dependent cell lines used in production of
vaccine and biopharmaceuticals. The following section will provide
insight into the adaptation of these MCs for MSC and hPSC expansion
and differentiation.
5. Propagation and differentiation of MSC on MCs
MSCs growas amonolayer on tissue culture treated polystyrene sur-
faces in serum containing or serum freemedia exhibiting ﬁbroblast-likemorphology (Fig. 1A). Cells are seeded at densities of 1–3 × 103 cells/
cm2 and at conﬂuence, average cell densities of 2.5 × 104 cells/cm2
can be achieved (Rowley et al., 2012). As shown in Table 1, MSC dosage
used in clinical applications can be as high as 6 billion cells for treating
Osteogenesis Imperfecta. Such large cell numbers would make the
current 2D cell culture platform technically and economically untena-
ble. It is therefore, imperative to consider microcarriers as the alterna-
tive platform (Rowley et al., 2012).
5.1. Selection of MCs for MSC expansion
Several types ofMCs having different surface chemistry,matrix, size,
and porosity have been tested for MSC propagation (Table 3). The
choice of the optimal MC depends mainly on the cell type and ﬁnal
use of the cells. Timmins et al. (2012) compared different MCs for
supporting proliferation of human placental derived MSCs. Seeding
efﬁciency was over 70% for several MCs (Cytodex 1, 3 and Cultispher
S). Cultispher S yielded the highest cell attachment rate (over 90%
efﬁciency) and a 15-fold cell expansion. Schop et al. (2010) tested a
similar set of MCs for the expansion of human bone marrow derived
MSCs. Cytodex 1 generated the highest seeding efﬁciency and growth,
achieving 4.8 fold expansion and ﬁnal cell density of about 6 × 105/ml.
Yang et al. (2007) tested Cytodex 1, Cytopore 2 and Cultispher S for
supporting rat bone marrow derived MSCs and again found Cultispher S
gave the best results. Goh et al. (2013) compared Cytodex (1 and 3) and
Cultispher MCs for supporting fetal human MSC and found that Cytodex
1 and 3 resulted in the highest cell yields (8 × 105 cells/ml). The study
chose Cytodex 3 instead of Cytodex 1 because it resulted in lower aggre-
gate formation rates and the collagen coating facilitated efﬁcient cell
harvesting at the end of the culture. In summary, in several studies
where different MCs were screened, Cultispher S, Cytodex 1 and 3
MCs were usually selected for the expansion of MSCs. The choice of
MC depends on the particular cell line, cell growth morphology,
and harvesting efﬁciency.
Table 3
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use of the ﬁnal product. In operations where single cell suspensions
are needed for seeding on scaffolds or for direct infusion, thennon-biodegradable MCs like dextran-based Cytodex or polystyrene-
based MCs from Thermo Scientiﬁc can be used. However, in cases
where MCs covered cells are seeded directly onto a scaffold or into
1040 A.K.-L. Chen et al. / Biotechnology Advances 31 (2013) 1032–1046the body, then biodegradable MCs, like gelatin-based Cultispher are
needed. There are several reports demonstrating the use of the gelatin
based biodegradable Cultispher MCs for direct transplantation. Yang
et al. (2007) used these types of MCs for in vivo transplantation in
which the MCs covered with rat BM MSCs were implanted into bone
defects. A second report from Chen et al. (2011b) used these MCs for
in vitro generation of centimeter-sized bone tissue. Zhou et al. (2011)
used experimentally produced biodegradable MCs like gelatin beads
and fabricated micronized dermal matrix and small intestinal sub mu-
cosa for direct implantation into mice. The main concern when using
these types of MCs is the issue of safety like biocompatibility of the
MC matrix in the body. Zhou et al. (2011) reported good compatibility
of the experimentally produced MCs. Further work is needed in order
to generate current Good Manufacturing Practices (cGMP) compliant
biodegradable MCs and to prove their biocompatibility.5.2. Culturing of MSC on MCs
For preliminary screening of culture conditions, MC cultures are
carried out in lab scale devices like petri dishes and tubes, which can
operate either in static or agitated conditions (Timmins et al., 2012;
Yang et al., 2007). However, demonstration of scalability is limited as
most of the studies were performed in 100–250 ml spinner ﬂasks
(Fig. 1C), without regulation of oxygen and pH (Table 3). In these
cultures, MSCs are seeded at a concentration of 3–5 cells per bead
achieving 7–20 fold expansion. Under optimal conditions, cell conﬂuency
on MC is about 50 cells per Cytodex 3 bead and a surface density of
2–4 × 104 cells/cm2 can be achieved (Fig. 1B). Volumetric cell yields
between 2 and 10 × 105 cells/ml have been reported, depending on the
cell type and the culture conditions (Table 3).
Most of the works cited in the preceding paragraph were conducted
in fetal calf serum containing media. For cGMP production, xeno-free
deﬁned media would be preferred. Santos et al. (2011a) used polysty-
rene based MCs coated with xeno-free proprietary cell adhesive
substrate (CELLstart™, Life Technologies) in order to propagate adipose
and bone marrow derived MSCs in a serum free spinner ﬂask culture,
achieving cell densities of 1.4 × 105 and 2 × 105 cells/ml respectively
(cell fold expansions of 14 and 18 respectively).
Usually an extensive medium replenishment regime, every
2–3 days, is required to achieve high cell densities. This feeding regime
is excessive, costly and unsuitable for large scale production. Limited
work has been undertaken to optimize the feeding regimes (Eibes et
al., 2010; Sart et al., 2010; Schop et al., 2010; Sun et al., 2010). Thus, a
reasonably priced xeno-free medium with optimally designed feeding
regime will serve to enable the large scale production of MSCs. In addi-
tion, more detailed studies on MSC metabolism, requirements for
essential growth factors and the development of efﬁcient nutrient and
growth factor feeding strategies will be important to reduce production
costs.5.3. Scaling up MC culture for MSC expansion
The scale-up of MSC MC cultures in large bioreactors has not been
reported in the literature. Preliminary data on potential scale-up in
theWave reactor has been reported by Timmins et al. (2012). Recently,
Goh et al. (2013) used a pH and dissolved oxygen controlled 1 l biore-
actor to demonstrate the scalability of a human fetal MSC culture; a
yield of 8 × 105 cells/ml was obtained. Several groups (Frauenschuh
et al., 2007; Sart et al., 2010; Schop et al., 2010) have provided prelimi-
nary spinner culture data describing the potential use of bead-to-bead
cell transfer for culture scale up. The effect of spinner impeller geometry
on cell expansion was investigated by Hewitt et al. (2011). These
studies pave theway formorework in developing a scalable production
system in controlled reactors (Fig. 1D).5.4. Cell harvesting
One of the main obstacles of using MC culture for propagating
MSCs is efﬁcient cell harvesting from the MC surface and separation
of the MCs from the harvested cells. This issue has received little
attention until now. Recently, Goh et al. (2013) have compared the
use of trypsin, recombinant cell dissociation enzyme TryPLE Express
(Life Technologies) and Collagenase I for harvesting MSC expanded
on Cytodex 3 MCs. Trypsin was found to be the most suitable enzyme
with highest cell detachment rate of more than 80% in 5 min without
signiﬁcantly affecting the harvested cell viability. MSCs harvested
from Cytodex 3 were further characterized and compared to those
harvested from tissue culture ﬂasks. No signiﬁcant differences were
found between MSC harvested from these two culturing platform in
terms of their immuno-phenotype, self-renewal capacity and prolifer-
ation potential (Goh et al., 2013). Currently, investigations on the
scalability and the integration of cell harvesting with the bioreactor
platform are in progress.
5.5. Differentiation
In most of the above studies the potential of the MC propagated
MSCs to differentiate to the three mesoderm lineages is demonstrat-
ed, mainly by histological data without performing a quantitative
assessment of differentiation efﬁciency to a speciﬁc lineage and test-
ing in vivo functions. There are a few preliminary reports demonstrat-
ing directed differentiation of MSC from MC cultures to a speciﬁc
lineage. Zhou et al. (2011) expanded human adipose derived MSCs
in MC culture and described their in vivo use in soft tissue skin regen-
eration in a nude mouse model. Tseng et al. (2012) later reported
spontaneous osteogenesis of MSCs due to alteration of cytoskeletal
tension in 3D MC cultures. Chen et al. (2011b) used aggregated
cell-MC structures to generate large cm size bone structures in a
perfusion chamber. Yang et al. (2007) described in vivo transplanta-
tions of bone marrow derived rat MSCs on MCs into rat bone defects
and examined in vivo osteogenesis. Recently Goh et al. (2013) have
quantiﬁed the in vivo and in vitro osteogenesis efﬁciencies of fetal
human MSCs propagated in MC cultures. Results show that cells
propagated on MCs exhibit higher levels of calcium deposit when
differentiated on polycaprolactone scaffold or transplanted into
mice, as compared with MSCs harvested from 2D culture.
6. Propagation and differentiation of human pluripotent
stem cells on MCs
Classical expansion of human pluripotent stem cells (hPSC), which
includes human embryonic stem cells (hESC) and induced pluripo-
tent stem cells (hiPSC), are usually carried out in 2D tissue culture
plates (Fig. 2A). This 2D culturing platform may be sufﬁcient for
early clinical trials or cell therapy that requires a small number of
cells, such as retinal pigment epithelial cells for treatment of macular
diseases. However, there is a need for a scalable expansion platform
to produce differentiated cells like cardiomyocytes and hepatocytes
from hPSC to meet future cell therapies, requiring millions of cells
per adult patient or for drug testing applications.
Expansion and differentiation of hPSC using MCs with various
coatings have been demonstrated and proven to be feasible for large
scale production (Table 4). It is important to consider the choice of
MCs and the bioreactor operating conditions that not only affect the
cell growth but also impact pluripotency and lineage commitments.
This review will discuss critical factors affecting the culture of hPSC
on MCs and related bioreactor conditions.
Mouse embryonic stem cells, having been extensively studied in the
past, are not included in this review, due to their limited relevance to
clinical applications.
Fig. 2. Bioprocessing of hPSCs. Illustrations showing phase contrast image (A) 2D hESC colony culture, (B) Matrigel coated rod shape DE-53 and (C) spherical Cytodex 1 MC cultures.
(D) Differentiated neural progenitor cells on Matrigel coated DE-53 MCs. MCs are indicated with white arrows. Hematoxylin and eosin staining on sectioned neural progenitor cell
aggregates exhibited typical neural rosette morphology (red arrow). Scale bars indicate 200 μm.
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with advantages of reducing cost and simplifying cell harvesting.
These protocols have demonstrated scalability and achieved up to
1.89 × 106 cells/ml (17.7 fold expansion) (Amit et al., 2011) whileTable 4
Propagation of hPSC in microcarrier cultures.
Microcarriers Coating Reactor type Type of hPSC
HILLEX® II Conditioned
medium
Spinner ﬂask hESC ESI-017
Cytodex 3 Feeder cells or
Matrigel
Spinner ﬂask hESC H1 and H9
Collagen coated
HyQSphere
Matrigel Spinner ﬂask hESC H1 and H9
Cytodex 3 No coating Spinner ﬂask hESC H9
DE-53 Matrigel Spinner ﬂask hESC HES-3
Collagen coated
HyQSphere
Matrigel Stirred tank bioreactor hiPSC B12-3
hESC H1 and H9
Cytodex 3 Matrigel Stirred tank bioreactor hESC SCED™461
DE-53 and Cytodex 1 Matrigel or
Laminin
Spinner ﬂask hESC HES-3
Polystyrene beads Laminin or
Vitronectin
Static culture hESC HES-3




Spinner ﬂask hESC H9
DE-53 No coating Spinner ﬂask hESC HES-3 and H7maintaining pluripotency and normal karyotype. The key to effective-
ly establish the aggregate cultures is the formation of homogeneous
aggregateswith consistent size. This has been reported to be a challeng-
ing hurdle due to signiﬁcant loss of initial cell viabilities (28–76%)Maximal hPSC expansion Differentiation References
1.3 × 105 cells/ml (2.2 fold) EB formation and cardiomyocyte
(50–60% beating aggregates)
Phillips et al. (2008)
Not available EB formation Nie et al. (2009)
1.3 × 106 cells/ml
(13–17 fold)
>80% deﬁnitive endoderm
(FOXA2 and SOX17 positive)
Lock and
Tzanakakis (2009)
1.53 × 106 cells/ml
(6.8 fold)
EB formation Fernandes et al.
(2009)
3.51 × 106 cells/ml
(18 fold)
EB formation Oh et al. (2009)
3. 6 × 105 hiPSC/ml (7 fold) >80% Deﬁnitive endoderm
(FOXA2 and SOX17 positive)
Kehoe et al. (2010)
2.2 × 106 cells/ml (15 fold) EB formation Serra et al. (2010)
3.4 × 106 cells/ml (17 fold) EB formation Chen et al. (2011a)
1.3–1.5 × 106 cells/ml
(8.5 fold)
EB formation Heng et al. (2012)
6.1 × 106 cells/ml (20 fold) EB formation and neural lineages Bardy et al. (2013)
2.78 × 106 cells (28 fold) Not tested Marinho et al. (2013)
2.3–2.5 × 106 cells
(12–13 fold)
EB formation and neural lineages Chen et al. (submitted
for publication)
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overcome this, addition or increasing the concentration of growth
factors or inhibitors (Amit et al., 2011; Kehoe et al., 2010; Krawetz et
al., 2010; Larijani et al., 2011; Olmer et al., 2010; Singh et al., 2010),
and transient heat shock treatment (Singh et al., 2010) has been used
to improve cell viability. During the cultivation of the aggregate culture,
it is important to limit cell aggregate size as cells will have difﬁculty
accessing nutrients and growth factors to maintain self-renewal of
hPSCs (Amit et al., 2011; Chen et al., 2012). Disaggregation is performed
usually through manual manipulation, which might undermine the
scalability of the platform. An updated review regarding aggregate
cultures of hPSCs can be found in O'Brien and Laslett (2012). Hence,
aggregate culture will not be discussed further in detail due to the
scope of the review.
6.1. Selection of MCs for hPSC expansion
The selection of suitableMCs is the ﬁrst step to establish a MC based
platform. Different hPSC cell lines were propagated on variety of MCs.
Several groups have screened MCs for the cultivation of hPSC by exam-
ining initial cell attachment followed by monitoring cell growth over a
prolonged length of time (Chen et al., 2011a; Lock and Tzanakakis,
2009; Nie et al., 2009; Phillips et al., 2008). The reported data indicate
that the commercial MCs are not suitable for hPSC cultivation without
any surface modiﬁcation. It seems that similar to the 2D hPSC culturing
platform, Matrigel coating on MCs had a profound effect on improving
cell growth and pluripotency in long term cultures.
Chen et al. (2011a) shows that cell yields were higher in Matrigel
coated MCs by 1.9 to 18 fold compared to the uncoated ones. Cells cul-
tivated on Matrigel coated carriers exhibited high viability (over 90%)
with no necrosis or cell death. These cells can be cultured for many pas-
sages by transferring them directly into newMCs or plating them on 2D
plates. They have also screened different ECM components for hESC
growth and identiﬁed laminin as a suitable replacement for Matrigel
coating onMCs. Similar cell growth and pluripotentmarker expressions
levels were observed using Matrigel or laminin coated MCs. Later a
study by Heng et al. (2012) took the MC platform further by propagat-
ing hESCs on laminin and vitronectin coated MCs in serum free medi-
um. Both laminin and vitronectin coated MCs performed equally well
in long term culture with respect to cell growth, pluripotent marker
expressions, in vitro and in vivo pluripotency and karyotype. In the
attempt to eliminate the need for ECM coating, our group has identiﬁed
that by addition of ROCK inhibitor (Y27632) to the culture medium,
hPSCs can attach and grow on uncoated MCs obtaining similar cell
yields as ECMcoated oneswhile still upholding pluripotency and karyo-
type stability (Chen et al., submitted for publication).
There is no consensus regarding which would be the most suitable
MCs for hPSC expansion. A study by Chen et al. (2011a) has explored
the effect of size, shape, porosity, coating and surface charge of MCs
on hESC growth using ten readily available commercial MCs and
chromatographic materials. It was found that MC size and shape af-
fected the cell morphology. Spherical MCs like Cytodex 1 and 3 gener-
ated aggregates with more open structure (Fig. 2C and D). The rod
shape MCs (DE-53) on the other hand created more compact aggre-
gates (Fig. 2E and F). The degree of compactness increased with the
decrease in MC size. The increase in the compactness of the cell-MC
aggregates had a negative impact on cell yield, presumably due to
lack of nutrients for the cells in the center of the aggregates. Cytodex
3 coated with Matrigel has been utilized for hESC expansion by sever-
al researchers. Nie et al. (2009) have reported that the hESC line, H1
propagated on Matrigel coated Cytodex 3 has a doubling time of
35 h similar to the 2D plate culture, while Serra et al. (2009) showed
that hESC line SCED™461 grew slower with doubling time of 42.6 h.
Chen et al. (2011a) have also used coated Cytodex 3 MCs for prop-
agation of HES-3 cells generating an average cell density of 1.1 × 106
cells/ml after 7 days of cultivation (HES-3). Furthermore, Nie et al.(2009) showed that cryopreserved cells adhered to Cytodex 3, had
better viability and recovery (1.5–1.9 fold increase) when compared
to freely suspended colonies.
ECM coated DE-53 cylindrical positively charged MCs were used
extensively for propagation of four hESC lines and two hiPSC
(Bardy et al., 2013; Chen et al., 2010a, 2010c, 2011a; Oh et al.,
2009). Cell densities of 2.8–6.1 × 106 cells/ml (14–30 fold expan-
sion) were achieved within 7 days in stirred spinner ﬂask cultures.
This MC has high cell attachment rate (over 90% in 2 h). It generated
compact cell-MC aggregates efﬁciently, which can afford single cell
seeding and withstand agitated conditions, support growth of hPSC
on Matrigel, laminin and without coating in the presence of ROCK
inhibitor (Bardy et al., 2013; Chen et al., 2011a; Chen et al., submitted
for publication; Oh et al., 2009).
6.2. Culturing hPSC on MCs
hESCs cultured on MCs can expand to higher cell yields than those
on 2D plate culture. Oh et al. (2009) have shown that hESC MC
culture yields 2.4–4.3 fold more cells than those on 2D tissue culture
plate (maximal cell density of 3.5 × 106 cells/ml as compared 0.8–
1.5 × 106 cells/ml for 2D culture). The higher cell yield from the MC
cultures may be attributed to the larger surface area, better oxygen
and nutrient transfer (Oh et al., 2009).
Chen et al. (2010c) have also providedmore insight on hESCmetab-
olism when comparing MC to 2D cultures. In the presence of mouse
embryonic ﬁbroblast-conditioned medium, both 2D and MC cultures
had similar doubling times, whereas in serum free medium conditions
(StemPro®hESC SFMormTeSR®1 SFM), theMC cultures exhibited lon-
ger doubling times than those on 2D cultures. hESCs cultured on 2D
plates have more divergence in metabolite speciﬁc consumption or
production rates than those on MC cultures in conditioned and serum
free media, which indicate that MC environments are more consistent
than the 2D cultures. The difference in cell growth and metabolism
between 2D and MC also suggests a need to optimize special growth
media for MC expansion.
hESCs and hiPSCs grown on MCs have high ratios of lactate to
glucose conversion of 1.8–2.3. These values are higher than the values
found in other mammalian cells like Vero and hybridoma cells (1.67–
1.77) (Bardy et al., 2013; Chen et al., 2010c) showing the high glyco-
lytic activity of hPSCs. Lactate concentration can be as high as 25 mM
in the late stage of the culture (Chen et al., 2010c). Exposing hESC to
lactate as low as 11 mM can result in reduction in cell growth and
down-regulation of pluripotent markers. On the other hand, low
levels of ammonium are generated in hPSC cultures (0.5–0.8 mM).
Up to a level of 1 mM of lactate, no effects on cell growth and plurip-
otent marker expression were observed. Thus, cell yields can be
improved by applying a feeding regime with controlled glucose levels
at 1–1.5 g/l. By doing this, lactate accumulation was reduced which
resulted in 40% higher cell yields (Chen et al., 2010c). Further work
is needed to examine the metabolism of hPSCs on MCs in a controlled
bioreactor. The nutrient metabolism of hPSCs during differentiation
has not yet been explored.
6.3. Scaling up MC culture for hPSC expansion
Several research groups have demonstrated the feasibility of scaling
up hESC expansion in suspension by using the simpler spinner ﬂasks
(50–150 ml) without controls for pH and oxygen (Table 4). Serra et
al. (2010) took one step further by combining the MC technology in a
bioreactor with automated controls to demonstrate the scalability and
standardization of the MC platform for hESC expansion. The group
generated 2.17 × 106 cells/ml in 11 days with seeding density of
1.5 × 105 cells/ml, achieving 15-fold expansion. This limited informa-
tion on development of efﬁcient large scale hESC MC culture system
emphasizes the need for investigating key parameters, such as the
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agitation effects.
Conventionally, adherent cells cultured on tissue culture ﬂasks are
dissociated into single cells enzymatically prior to seeding onto MCs
in order to generate even distribution of cells on MCs. Otherwise,
the cell growth and yield might be compromised by uneven cell
growth on MCs. Early attempts of culturing hESCs on MCs by
Phillips et al. (2008) showed that adapting hESCs to single cell
seeding was an important step for the initiation of hESC MC culture.
Single cells had better survival when compared to aggregate seeding
generated by collagenase treatment. However, Oh et al. (2009) later
showed that hPSC clump seeding is also possible resulting in similar
cell yields. Single cell seeding as well as clump seeding results in gen-
eration of large cell-MC aggregates unlike other adherent cells (e.g.
MSC and Vero cells). To have consistent clump seeding of 2D hPSC
cells to initiate MC culture, the study used a cell scrapper (EZ passage
tool, Life Technologies) which generates uniform cell clumps. Under
static conditions, these cell-microcarrier aggregates would expand
by attaching to nearby MCs or MC-cell aggregates. Subsequent pas-
saging can be done by simply adding a fraction of MCs coated with
cells to new MC (Chen et al., 2010a). Thus single cell seeding is not
necessary for propagating cells on MCs but rather it is important to
generate uniform cell-MC aggregates.
Oxygen is one of the parameters that can affect hESC growth and
pluripotency, but there are conﬂicting reports on optimal oxygen
level required by hESCs. There are reports suggesting hypoxic condi-
tions are preferred for hESC growth and maintenance of in vitro
pluripotency (Covello et al., 2006; Forristal et al., 2010). However,
Serra et al. (2010) showed that dissolved oxygen control at 30% air
saturation yielded better cell growth when comparing to 5% air satu-
ration (hypoxic condition) in a controlled bioreactor. They have
reported that the different levels of oxygen had no signiﬁcant effect
on the expression level of the pluripotent marker SSEA 4. More re-
search is needed to clarify the controversy.
Another bioprocess parameter that can affect the quality of hESCs is
agitation. Lock and Tzanakakis (2009) showed that hESCs propagated
on MCs in spinner ﬂask were sensitive to the level of agitation speeds.
High agitation speed (80 rpm) resulted in lower cell yield and increased
the doubling time when compared to low agitation speed (45 rpm).
Another study has reported that different hESC lines propagated on
MCs can have different responses to agitation. Under the same agita-
tion condition, HES-3 displayed a decrease in expression of pluripo-
tent markers whereas no signiﬁcant change was observed in HES-2
(Leung et al., 2010). No improvementwas observedwhen ﬁve different
known cell protective polymers (Pluronic-F68, dextran, methylcellu-
lose, polyethylene glycol, and hyaluronic acid)were added into agitated
HES-3 MC cultures (Leung et al., 2010). The nature of MC coatings can
also affect hESC sensitivity to agitation. HES-3 propagated in agitated
spinner ﬂasks on laminin coated MCs exhibited a signiﬁcant reduc-
tion in expression of pluripotent markers when compared to
Matrigel coated ones (Chen et al., 2011a). Bardy et al. (2013) demon-
strated that hiPSC (IMR90) propagated on MCs exhibited improved
expressions of pluripotent markers under agitated condition when
medium exchanges (80% of total culture volume) was performed
twice instead of once per day. This suggests that metabolic condi-
tions in agitated culture can contribute to loss of pluripotency
(high lactate levels or low pH generated in the high density
cultures). In conclusion, the sensitivity of hPSCs to agitation can be
attributed not only to the agitation speed but also to the hPSC lines,
culture environment and the coatings on the MCs.
6.4. Cell harvesting
Selecting a suitable procedure and conditions for harvesting cells
from MCs is important for a successful process. The recombinant pro-
teolytic enzyme TryPLE Express is routinely used to detach hESCsfrom MCs followed by a 40 μm sieve to remove the MCs (Oh et al.,
2009). This study showed that harvested cells can be cultured subse-
quently onto fresh MCs and achieved a similar cell yield to those
seeded from cell-MC aggregates that were mechanically dissociated.
Other groups like Lock and Tzanakakis (2009) who harvested deﬁni-
tive endoderm cells from MCs used collagenase. Lecina et al. (2010)
developed a different harvesting method for cardiomyocytes from
MCs which used two enzymes (Collagenase IV and Trypsin) consecu-
tively. Cell harvest methods and conditions depend on the type of
cells and MC properties. There have been no systematic studies com-
paring the methods and conditions for harvesting hPSCs and their
differentiated progenies.
Another important point is that these methods are designed for
small scale and may not be directly translatable to a scaled-up process.
Systems developed for large scale harvesting of other adherent cell lines
may be adapted to hPSCs. For example, Lindskog et al. (1987) showed
the use of dextranase to remove cells cultured on dextran based MCs.
Billig et al. (1983) showed that MC-cell separation can be done by dif-
ferential centrifugation with Ficoll-Paque™. Rho-kinase inhibitor
Y27632, is reported to be effective in preventing dissociated hPSC
from undergoing apoptosis (Braam et al., 2010; Chen et al., 2010b;
Olson, 2008; Watanabe et al., 2007). Furthermore, since the harvested
cells are the actual product, any residual particles from the MCs should
also be removed. Recent development in thermo-sensitive MCs that
allow cell detachment via a change in temperature without using any
proteolytic enzyme appears quite promising. The thermo-sensitive
polymer, poly-N-isopropylacrylamide (pNIPAAm) has been extensively
studied. Culturing cells on pNIPAAm coupled MCs (e.g. Cytodex 3,
polystyrene, alginate, and polyhydroxyethylmethacrylate beads) has
been demonstrated, with efﬁcient cell detachment by decreasing culture
temperature from 37 °C to below 30 °C (Cetinkaya et al., 2011; Hendrick
et al., 2001; Kim et al., 2002; Tamura et al., 2012; Yang et al., 2010).
6.5. Differentiation
Differentiated or intermediate progenitor cells of hESCs are required
for cell therapy. Therefore, it would be ideal to combine expansion and
differentiation of hESCs on MCs within the bioreactor. However, it is a
challenge to establish an integrated MC based platform considering
that many of the differentiation protocols require several physical ma-
nipulations that may include replating, co-culturing, cell selection or
passaging. A few groups have had some success in this endeavor. Lock
and Tzanakakis (2009) demonstrated the generation of FOXA2 and
SOX17 positive deﬁnitive endoderm after hESC expansion on MCs.
The efﬁciency was signiﬁcantly higher (84.2%) onMCs when compared
to 63.2% in 2D culture. Cardiomyocyte differentiation is another area
where MC can play an important role in fulﬁlling the need to generate
large quantities of cells required for treatment of cardiac infracts.
Lecina et al. (2010) screened 5 differentMCs and found protamine coat-
ed TSKge1 Tresyl-5PW (Tosoh Bioscience) MCs (Ø 10 μm) to be the
optimal MCs for cardiomyocyte differentiation. The efﬁciency was 2 to
3-fold higher in MC culture with 0.28–0.62 cardiomyocyte generated
per hESC seeded comparing to 0.13–0.22 via embryoid bodies forma-
tion (Lecina et al., 2010; Ting et al., 2012). However, there are still
challenges ahead in developing integrated platforms combining hESC
expansion and cardiac differentiation. The bottleneck seems to be at
the generation of ideal hESC-MC aggregates prior to differentiation
(our unpublished data). Bardy et al. (2013) have also made progress
in neural differentiationwithMCs. Combining 7 days of hESC expansion
with seeding density of 2 × 105 cells/ml and 16 day neural differentia-
tion on MCs, more than 300 PSA-NCAM positive neural progenitor cells
(NPC) per seeded hESC were generated.
One of the major concerns in clinical applications of cells derived
from hPSCs is the removal of undifferentiated cell populations,
which can generate teratomas after transplantation. To achieve this,
several cell separation methods are suggested. For small scale,
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isolating neural cells (Pruszak et al., 2007), cardiomyocyte (Dubois
et al., 2011; Uosaki et al., 2011; Xu, 2012) and endothelial cells
(Levenberg et al., 2002). A scalable Percoll density centrifugation
method has been used in cardiomyocyte separation achieving purity
of 70–95% (Cao et al., 2008; Laﬂamme et al., 2007; Xu, 2012; Xu et al.,
2002). An immunomagnetric cell sorting platform, which currently
is considered as the “gold standard” (Thiel et al., 1998) was described
by Schriebl et al. (2010). Other innovative approaches include the
development of a cytotoxic antibody to hPSC (Choo et al., 2008) and
generation of recombinant hPSC with speciﬁc expression systems that
can eliminate non-differentiated cell populations (Anderson et al.,
2007; Huber et al., 2007). Each of these methods has advantages and
ﬂaws. Hence, developing an integrated multi-stage cell separation
platform is imperative. Schriebl et al. (2012) has demonstrated this
concept, where the coupling of immunomagnetic cell sortingwith cyto-
toxic antibody treatment reduced the risk of teratoma formation of pu-
riﬁed hESC derived progenitors.7. Conclusions and future trends
MCs are a robust and scalable platform for culturing adherent cell
lines. It has taken more than four decades from their ﬁrst invention in
1967 by van Wezel, for the technology to be fully developed and ma-
tured. To date, the use of MCs has been limited mainly to vaccine pro-
duction and research applications. However, with the increase in
importance of stem cell bioprocessing, in the last ﬁve years, the inter-
est in using the MC platform for this application has re-appeared and
a new wave of research towards ﬁnding solutions to the difﬁculties in
the expansion of stem cells by using MCs have emerged.
The adaptation of MSCs onto the MC platform has been straight-
forward since they grow as monolayer cultures similar to other
mammalian adherent cell lines. Thus many of the earlier MC studies
can be directly adapted. However still more research is needed in
several critical issues: the development of reasonably priced chemi-
cally deﬁned xeno-free media, ﬁnding an efﬁcient large scale cell
harvesting method and exploring the interrelations between cell
expansion on MCs and the efﬁciency of differentiation. Moreover,
development of biodegradable MCs can be advantageous as MSCs
grown on these MCs can be used as the scaffold for in vivo
transplantation.
The adaptations of hPSCs onto the MC platform are more
challenging than MSCs as these cells grow in multilayer colonies
on ECM based matrices. In order to make the MC platform viable,
there is a need to optimize properties of MCs (e.g. coating, size
and materials). Moreover, due to the need for maintaining
pluripotency at the expansion phase and achieving efﬁcient
differentiation at the following step, MCs can also be engineered
to include other innovative properties like growth factor encapsu-
lation and bio-active matrices, which can facilitate hPSC expansion,
differentiation and also preferably in vivo transplantation. Beside
issues related to MC structure and its composition there is a need
to develop special large scale systems as the hPSC MC platform
may not be adapted easily to conventional bioreactors due to
shear stress effects. Reasonably priced xeno-free small molecule
based media, efﬁcient feeding regimes, and most importantly the
development of efﬁcient integrated cell expansion and differentia-
tion processes as well as the downstream harvesting and selection
of the desired cells are needed.
In conclusion, the classical MC platform which was developed for
biologics production by adherent cells is not optimal for stem cells.
There is a need to modify MC technologies and the associated pro-
cesses which must be tailored to the requirements of the stem cell
types of interest, and the clinical applications where they will be
used.Acknowledgment
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